This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Flecainide

Authoring team

Flecainide is a class IC antiarrhythmic drug.

Flecainide should be used cautiously because:

  • it is moderately negatively inotropic
  • it is arrhythmogenic
  • it increases mortality post-MI

The summary of product characteristics must be consulted before using this drug.

Notes:

  • SCN5A gene polymorphism histidine-558-to-arginine (H558R) is more prevalent in patients with atrial fibrillation (AF) compared with the general population and its presence is associated with a more favourable response to flecainide treatment (1)

Reference:

  • Trincado Ave M, Brion M, Blanco-Verea A, et al.Prevalence and relevance of H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study.Heart Published Online First: 01 November 2024.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.